SEARCH

SEARCH BY CITATION

References

  • 1
    Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307:573582.
  • 2
    Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011; 364:22932304.
  • 3
    Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008; 299:173184.
  • 4
    Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379: 617624.
  • 5
    Claus H, Jordens MS, Kriz P, et al. Capsule null locus meningococci: typing of antigens used in an investigational multicomponent meningococcus serogroup B vaccine. Vaccine 2012; 30:155160.
  • 6
    Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010; 50(Suppl 2):S37S44.
  • 7
    Cramer JP, Wilder-Smith A. Meningococcal disease in travelers: update on vaccine options. Curr Opin Infect Dis 2012; 25:507517.
  • 8
    Wilder-Smith A. Meningococcal vaccines: a neglected topic in travel medicine? Expert Rev Vaccines 2009; 8: 13431350.
  • 9
    Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184191.
  • 10
    Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep 2007; 56:794–795.
  • 11
    Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep 2009; 58: 1042–1043.
  • 12
    Harrison LH, Pelton SI, Wilder-Smith A, et al. The global meningococcal initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 2011; 29:33633371.
  • 13
    Bruce MG, Rosenstein NE, Capparella JM, et al. Risk factors for meningococcal disease in college students. JAMA 2001; 286:688693.
  • 14
    Centers for Disease Control, R.O.C. (Taiwan), current immunization schedule. Available at: http://www.Cdc. Gov.Tw/english/list.Aspx?Treeid=e79c7a9e1e9b1cdf&nowtreeid=9aca97f87d31282d. (Accessed 2013 Jan 22).
  • 15
    Huang HL, Chiu TY, Huang KC, et al. Travel-related mosquito-transmitted disease questionnaire survey among health professionals in Taiwan. J Travel Med 2011; 18:3438.